ABAnnegien Broeks

Annegien Broeks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annegien Broeks has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A polymorphism in the coding sequence of WT1 is an independent prognostic marker in 1,101 patients with lobular breast cancer.

    by M. Heuser, F. Damm, P. Schuermann, M. Zucknick, M. Shah, P. Harrington, P. Pharoah, M. Schmidt, A. Broeks, R. van Hien, et al.

    10558 Background: We have recently shown that a single nucleotide polymorphism (SNP) in WT1 exon 7 (rs16754) is associated with prognosis in patients with acute myeloid leukemia. To test whether SNP rs16754 is also associated with outcome in other cancers, we investigated the role of this SNP as a candidate polymorphism for breast cancer (BC) survival in a large cohort of BC patients in the context of other prognostic markers. Methods: WT1 SNP rs16754 was genotyped using a TaqMan genotyping assay and genomic DNA from 8,337 BC patients from four European studies of the Breast Cancer Association Consortium (BCAC). The effect of rs16754 genotypes on overall survival was assessed in univariate and multivariate analysis adjusting for known prognostic markers. Results: The minor allele of SNP rs16754 was found heterozygous in 25.2% and homozygous in 2.8% of all studied BC patients. Patient characteristics and pathologic findings were similarly distributed between patients homozygous for the major allele compared to patients heterozygous or homozygous for the minor allele. Overall survival (OS) of patients with lobular BC and at least one minor allele of WT1 SNP rs16754 was significantly shorter compared to patients with lobular BC who were homozygous for the major allele (HR 1.54, 95% CI 1.15 to 2.06, P=.004; 10-year OS 71% vs 81%. Importantly, breast cancer specific survival (BCSS) was significantly shorter in lobular BC patients with at least one minor allele of SNP rs16754 compared to patients who were homozygous for the major allele (HR, 1.55, 95% CI 1.13 to 2.14 , P=.007). In patients with invasive lobular BC (n=1,101), SNP rs16754 status was an independent predictor of OS and BCSS in multivariate analysis (HR 1.44, 95% CI 1.06-1.94, P=.018 and HR 1.49, 95% CI 1.07-2.07, P=.018, respectively) adjusting for nodal status, ER, PR, HER2 status, tumor grade and age. The unfavorable effect of SNP rs16754 became most apparent five years after diagnosis, and was strongest in hormone-receptor positive and in younger patients with lobular BC. Conclusions: WT1 SNP rs16754 may therefore become useful as an independent poor-risk marker in lobular breast cancer patients that might improve risk and treatment stratification.

  • Open Access

    The spectrum of ATM missense variants and their contribution to contralateral breast cancer

    by Annegien Broeks, Linde M. Braaf, Angelina Huseinovic, Marjanka K. Schmidt, Nicola S. Russell, Flora E. van Leeuwen, Frans B. L. Hogervorst, Laura J. Van ‘t Veer

    Heterozygous carriers of ATM mutations are at increased risk of breast cancer. In this case-control study, we evaluated the significance of germline ATM missense variants to the risk of contralateral breast cancer (CBC). We have determined the spectrum and frequency of ATM missense variants in 443 breast cancer patients diagnosed before age 50, including 247 patients who subsequently developed CBC. Twenty-one per cent of the women with unilateral breast cancer and 17% of the women with CBC had at least one ATM germline missense variant, indicating no significant difference in variant frequency between these two groups. We have found that carriers of an ATM missense mutation, who were treated with radiotherapy for the first breast tumour, developed their second tumour on average in a 92-month interval compared to a 136-month mean interval for those CBC patients who neither received RT nor carried a germline variant, (p = 0.029). Our results indicate that the presence of ATM variants does not have a major impact on the overall risk of CBC. However, the combination of RT and (certain) ATM missense variants seems to accelerate tumour development.


    • 1 March 2003
      • Vol. 147  (9) , 386-9

    [From gene to disease; ataxia telangiectasia].

    by A Broeks, L J Van 't Veer, C Ottenheim, J A P Hiel, W J Kleijer, C Weemaes

    Ataxia telangiectasia (AT) is an autosomal recessive disorder characterised by cerebellar ataxia, telangiectasia, immune defects, and a predisposition to malignancy. Chromosomal breakage is a feature. AT cells are abnormally sensitive to cell kill by ionising radiation and abnormally resistant to inhibition of DNA synthesis by ionising radiation. The responsible gene, 'ataxia telangiectasia mutated' (ATM) plays a crucial role in a signal transduction pathway, regulating the cell cycle, and in preventing damaged DNA from being reproduced. This rare genetic disorder manifests itself during childhood. The illness is progressive and most individuals die in their second or third decade of life due to infections or cancer. AT is difficult to diagnose due to its rarity and clinical heterogeneity. Both a physical examination and several laboratory tests are necessary for establishing its proper diagnosis.